Pharyngeal Electrical Stimulation Included in New AHA/ASA Guidelines for Stroke Recovery

New Guidelines for Stroke Rehabilitation

In a landmark update, the American Heart Association (AHA) and American Stroke Association (ASA) have recognized pharyngeal electrical stimulation (PES) in their 2026 guidelines for stroke rehabilitation. This shift represents the first significant update in a decade, signaling a change in how healthcare providers can approach rehabilitation for patients with severe dysphagia due to strokes.

The updated guidelines, published on August 27, 2026, in the journal Stroke, specifically recommend PES as a potential therapy to improve swallowing function in individuals experiencing severe swallowing difficulties, known as dysphagia, post-stroke. This recommendation reflects a broader understanding of the complexities of stroke recovery and rehabilitation, extending well beyond mere survival. As per the guidelines, PES may help patients regain their ability to eat and drink safely, reduce the risk of negative health consequences, and markedly enhance their quality of life.

Phagenesis, the commercial stage company responsible for developing the Phagenyx® System, is at the forefront of this advancement. The Phagenyx System is recognized as the first and only commercially available device that delivers pharyngeal electrical stimulation. According to Chad Hoskins, CEO of Phagenesis, the recognition of PES aligns with their mission to restore independence and dignity for patients post-stroke.

Dysphagia is a prevalent issue faced by up to 45% of stroke patients, often leading to severe complications, including a threefold increase in the risk of pneumonia and significantly longer hospital stays. The potential to incorporate PES into treatment protocols offers a novel approach to address these challenges and improve patient outcomes.

The new guideline also builds upon earlier recommendations made in January 2026, which included PES in the AHA/ASA’s directive for the early management of patients following an acute ischemic stroke. This continuity underscores the method's clinical relevance across the entire spectrum of stroke care.

Evidence gathered over the last decade, including systematic reviews, meta-analyses, and several randomized controlled trials, has substantiated the effectiveness of PES in enhancing recovery. Industry professionals acknowledge that the presence of an evidence-based tool recognized across various phases of stroke care furnishes clinicians with a robust framework for addressing dysphagia effectively at any stage in the recovery process.

Dr. Les Fuchs, a regional director of Rehabilitation Services at North Baptist Health South Florida, stated that dysphagia remains a significant barrier to recovery beyond the ICU, reinforcing the importance of having established guidelines that clinicians can rely on.

Phagenesis boasts extensive clinical data supporting the efficacy of the Phagenyx System, comprising over 30 peer-reviewed studies and nine randomized controlled trials. Findings from these studies reveal improved swallowing safety, decreased dysphagia severity, increased return to oral nutrition, and overall shorter hospital stays for those undergoing treatment with PES.

Phagenesis, founded in 2007 and headquartered in Manchester, U.K., with its U.S. operations located in Nashville, is making significant strides in transforming recovery from severe post-stroke dysphagia through its innovative technology. With FDA clearance for its device and CE-mark approval in Europe, the company stands poised to further enhance the quality of care provided to stroke survivors. As PHagenesis continues to evolve, it represents a significant player in the landscape of stroke rehabilitation, pushing forward the boundaries of what is possible for patients in need of specialized care.